---
title: "Brainstorm Cell | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286615451.md"
datetime: "2026-05-15T21:02:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286615451.md)
  - [en](https://longbridge.com/en/news/286615451.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286615451.md)
---

# Brainstorm Cell | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.19, beating the estimate of USD -0.36.

EBIT: As of FY2026 Q1, the actual value is USD -2.046 M.

Brainstorm Cell Therapeutics Inc. announced its financial results for the quarter ended March 31, 2026, through a press release issued on May 15, 2026, which was furnished as Exhibit 99.1 to a Form 8-K report. Specific financial and operational metrics, as well as any outlook or guidance, are not detailed within the provided Form 8-K filing itself, however, the following information was included in the reference .

#### Financial Performance (Three Months Ended March 31, 2026)

-   Cash, cash equivalents, and restricted cash were approximately $0.2 million as of March 31, 2026, compared to approximately $0.3 million as of December 31, 2025 .
-   Research and development expenditures, net, were approximately $0.8 million, a decrease from approximately $1.3 million for the three months ended March 31, 2025 .
-   General and administrative expenses were approximately $1.3 million, down from approximately $1.8 million for the three months ended March 31, 2025 .
-   Net loss for the three months ended March 31, 2026, was approximately - $2.1 million, an improvement from a net loss of approximately - $2.9 million for the three months ended March 31, 2025 .
-   Operating loss was - $2,046 thousand, compared to - $3,089 thousand for the same period in 2025 .
-   Financial income (expense), net, was - $81 thousand, compared to $46 thousand for the same period in 2025 .
-   The change in fair value of warrant liability was $0, compared to $179 thousand for the same period in 2025 .

#### Balance Sheet Highlights (As of March 31, 2026)

-   Cash and cash equivalents were $15 thousand, down from $29 thousand as of December 31, 2025 .
-   Total current assets were $184 thousand, compared to $307 thousand as of December 31, 2025 .
-   Total assets were $755 thousand, decreasing from $1,022 thousand as of December 31, 2025 .
-   Total current liabilities were $11,764 thousand, an increase from $11,007 thousand as of December 31, 2025 .
-   Total liabilities were $11,764 thousand, up from $11,007 thousand as of December 31, 2025 .
-   Total stockholders’ deficit was - $11,009 thousand, compared to - $9,985 thousand as of December 31, 2025 .

#### Corporate Financing

-   In February 2026, Brainstorm Cell Therapeutics Inc. secured a total of $2 million in funding through two strategic private placement agreements, each consisting of stock and warrants .

#### Outlook / Guidance

Brainstorm Cell Therapeutics Inc. is focused on completing the final steps to initiate its planned Phase 3 ENDURANCE study of NurOwn in ALS, with ongoing progress in site activation, manufacturing readiness, and regulatory engagement. The company anticipates that successful completion of Part A of the study will generate the clinical data required to support a new Biologics License Application (BLA) submission for NurOwn. The initiation of the enrollment phase is contingent upon securing the necessary financing .

### Related Stocks

- [BCLI.US](https://longbridge.com/en/quote/BCLI.US.md)

## Related News & Research

- [Burford Capital announces 2Q26, YTD26 financial results in Form 8-K](https://longbridge.com/en/news/295104022.md)
- [HSIC: Strong Q2 2026 results drove raised FY2026 guidance and continued share repurchases](https://longbridge.com/en/news/294806433.md)
- [VAALCO Energy declares Q3 2026 dividend of $0.0625 per share](https://longbridge.com/en/news/295144692.md)
- [Mobilezone schedules investor video conference on H1 2026 results](https://longbridge.com/en/news/294935560.md)
- [VGP to host webcast on H1 2026 results](https://longbridge.com/en/news/295056101.md)